The company's drugs are formulated in a cosmetically elegant gel that is applied to the skin, enabling local suppression of the Ras/Raf/MEK/ERK pathway that drives the pathology of rare cutaneous RASopathies, allowing doctors to eliminate significant systemic adverse events observed with orally administered MEK inhibitors.